,Outcomes,Arm 1,Arm 2
0,intervention,olanzapine,haloperidol
1,Five of six,CGI Improvement item,CGI Improvement item
2,three of six,CGI Improvement item,CGI Improvement item
3,haloperidol,Five of six,
4,responders,CGI Improvement item,CGI Improvement item
5,CGI Improvement item,responders,responders

,Outcomes,Arm 1,Arm 2
0,intervention,secretin,placebo
1,change of ADOS social-communication total score,secretin,secretin
2,no,0.346,0.346
3,-0.8 +/- 2.9,0.346,0.346
4,-0.6 +/- 1.4,0.346,0.346
5,0.346,-0.6 +/- 1.4,-0.6 +/- 1.4

,Outcomes,Arm 1,Arm 2
0,intervention,49 children,placebo
1,101,randomly assigned,randomly assigned
2,82,randomly assigned,randomly assigned
3,19,randomly assigned,randomly assigned
4,8.8+/-2.7,randomly assigned,randomly assigned
5,randomly assigned,placebo,placebo
6,49 children,randomly assigned,52
7,52,8.8+/-2.7,8.8+/-2.7

,Outcomes,Arm 1,Arm 2
0,intervention,0.5 to 3.5 mg,placebo
1,0.5 to 3.5 mg,14.1 percent,
2,56.9 percent,14.1 percent,Irritability score
3,reduction in the,placebo,placebo
4,Irritability score,placebo,placebo
5,14.1 percent,Irritability score,Irritability score

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,placebo
1,rate of a positive response,52,52
2,at least a 25 percent decrease in the Irritability score,52,52
3,rating of much improved or very much improved on the CGI-I,52,52
4,69 percent,52,52
5,34 of 49,52,52
6,positive response,52,52
7,12 percent,52,52
8,placebo,69 percent,
9,6 of,52,52
10,52,6 of,6 of

,Outcomes,Arm 1,Arm 2
0,intervention,Risperidone,placebo
1,weight gain,placebo,placebo
2,2.7+/-2.9 kg,weight gain,0.8+/-2.2 kg
3,0.8+/-2.2 kg,weight gain,weight gain

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,placebo
1,64 %,31 %,placebo
2,improvement over baseline in the irritability score,placebo,placebo
3,31 %,improvement over baseline in the irritability score,improvement over baseline in the irritability score

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,placebo
1,87 %,global improvement in their condition,40 %
2,global improvement in their condition,placebo,placebo
3,40 %,global improvement in their condition,global improvement in their condition

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,7.7 %
1,Somnolence,manageable,manageable
2,72.5 %,manageable,manageable
3,7.7 %,manageable,manageable
4,manageable,placebo,placebo

,Outcomes,Arm 1,Arm 2
0,intervention,-treated group,placebo
1,Eight ( 53 % ) of 15 patients,none of 15,responders
2,responders,placebo,placebo
3,none of 15,responders,responders

,Outcomes,Arm 1,Arm 2
0,intervention,FM,early CR
1,Median FFS,53 months,53 months
2,36 months,53 months,53 months
3,19 months,53 months,53 months
4,53 months,19 months,19 months

,Outcomes,Arm 1,Arm 2
0,intervention,IT methotrexate,triple IT therapy
1,19.5 %,Processing Speed Index score,6.9 %
2,Processing Speed Index score,triple IT therapy,triple IT therapy
3,6.9 %,Processing Speed Index score,Processing Speed Index score

,Outcomes,Arm 1,Arm 2
0,intervention,AMB,41
1,58 %,0.05,0.05
2,36,41,80 %
3,completed prophylaxis,0.05,0.05
4,80 %,0.05,0.05
5,41,completed prophylaxis,completed prophylaxis
6,FLU,58 %,
7,0.05,41,80 %

,Outcomes,Arm 1,Arm 2
0,intervention,tamoxifen,placebo
1,6074,severe angina,severe angina
2,tamoxifen,severe angina,severe angina
3,6072,severe angina,severe angina
4,placebo,1.75 ( 0.44 to 8.13 ),
5,95 %,severe angina,severe angina
6,1.75 ( 0.44 to 8.13 ),severe angina,severe angina
7,fatal myocardial infarction,severe angina,severe angina
8,1.11 ( 0.55 to 2.28 ),severe angina,severe angina
9,nonfatal myocardial infarction,severe angina,severe angina
10,0.69 ( 0.29 to 1.57 ),severe angina,severe angina
11,unstable angina,severe angina,severe angina
12,0.83 ( 0.32 to 2.10 ),severe angina,severe angina
13,severe angina,0.83 ( 0.32 to 2.10 ),0.83 ( 0.32 to 2.10 )

,Outcomes,Arm 1,Arm 2
0,intervention,tamoxifen,placebo
1,CHD,severe angina,severe angina
2,516,severe angina,severe angina
3,532,severe angina,severe angina
4,placebo,1.25 ( 0.32 to 5.18 ),
5,risk ratios,severe angina,severe angina
6,95 %,severe angina,severe angina
7,0.00 ( 0 to 1.58 ),severe angina,severe angina
8,fatal myocardial infarction,severe angina,severe angina
9,1.25 ( 0.32 to 5.18 ),severe angina,severe angina
10,nonfatal myocardial infarction,severe angina,severe angina
11,2.26 ( 0.87 to 6.55 ),severe angina,severe angina
12,unstable angina,severe angina,severe angina
13,1.39 ( 0.23 to 9.47 ),severe angina,severe angina
14,severe angina,1.39 ( 0.23 to 9.47 ),1.39 ( 0.23 to 9.47 )

,Outcomes,Arm 1
0,intervention,psychosocial therapy
1,Risk of cardiovascular death,psychosocial therapy
2,86 %,Risk of cardiovascular death

,Outcomes,Arm 2,Arm 1
0,intervention,control,ventricular arrhythmias
1,Six,ventricular arrhythmias,cardiovascular deaths
2,seven,ventricular arrhythmias,cardiovascular deaths
3,cardiovascular deaths,ventricular arrhythmias,control

,Outcomes,Arm 1
0,intervention,therapy group
1,risk of all-cause mortality,therapy group
2,62 %,risk of all-cause mortality

,Outcomes,Arm 1,Arm 2
0,intervention,therapy group,eight
1,three,deaths,deaths
2,deaths,control group,control group
3,eight,deaths,deaths

,Outcomes,Arm 2,Arm 1
0,intervention,losartan,50 mg
1,50 mg,50 mg,
2,captopril,,50 mg
3,tolerated,50 mg,50 mg

,Outcomes,Arm 1,Arm 2
0,intervention,all-cause mortality,447 ( 16 % )
1,primary end point,captopril,captopril
2,all-cause mortality,deaths,deaths
3,499 ( 18 % ),deaths,deaths
4,447 ( 16 % ),deaths,deaths
5,deaths,captopril,captopril
6,captopril,499 ( 18 % ),

,Outcomes,Arm 1,Arm 2
0,intervention,losartan,captopril
1,cardiovascular deaths,captopril,captopril
2,"420 , 15 %",cardiovascular deaths,"363 , 13 %"
3,"363 , 13 %",cardiovascular deaths,cardiovascular deaths

,Outcomes,Arm 1,Arm 2
0,intervention,Losartan,captopril
1,Losartan,captopril,captopril
2,tolerated,captopril,captopril
3,captopril,17,fewer patients discontinuing
4,fewer patients discontinuing,captopril,captopril
5,17,23 %,23 %
6,23 %,losartan,losartan

,Outcomes,Arm 1,Arm 2
0,intervention,35 mg,125 mg
1,incidence of ICD therapies per patient-year,0.31,0.31
2,36,0.31,0.31
3,10,0.31,0.31
4,12,0.31,0.31
5,9,0.31,0.31
6,35 mg,,125 mg
7,75 mg,0.31,0.31
8,125 mg,0.31,0.31
9,0.31,12,9

,Outcomes,Arm 1
0,intervention,metoprolol CR/XL
1,left ventricular ejection fraction,122 to 145 ms
2,0.26 to 0.31,duration of the late mitral filling wave ( A )
3,deceleration time of the early mitral filling wave ( E ),122 to 145 ms
4,189 to 246 ms,122 to 145 ms
5,time velocity integral of E-wave,122 to 145 ms
6,8.7 to 11.2 cm,122 to 145 ms
7,duration of the late mitral filling wave ( A ),122 to 145 ms
8,122 to 145 ms,duration of the late mitral filling wave ( A )

,Outcomes,Arm 2
0,intervention,placebo
1,No,changes

,Outcomes,Arm 1,Arm 2
0,intervention,Bronchodilators,0.21
1,reduced peripheral airways resistance,increased measures of compliance,increased measures of compliance
2,0.53,increased measures of compliance,increased measures of compliance
3,0.38,increased measures of compliance,increased measures of compliance
4,controls,0.38,
5,0.21,0.38,reduced peripheral airways resistance
6,0.19,0.38,reduced peripheral airways resistance
7,increased measures of compliance,controls,0.19

,Outcomes,Arm 1,Arm 2
0,intervention,Magnesium,Magnesium
1,reduced the,shivering threshold,
2,shivering threshold,reduced the,
3,36.3 [ SD 0.4 ] degrees C,shivering threshold,36.6 [ 0.3 ] degrees C
4,36.6 [ 0.3 ] degrees C,shivering threshold,

,Outcomes,Arm 1,Arm 2
0,intervention,HBI,usual care
1,reducing unplanned hospitalization,usual care,usual care
2,677,readmissions,824
3,readmissions,usual care,usual care
4,824,readmissions,readmissions

,Outcomes,Arm 1,Arm 2
0,intervention,CCM,180 +/- 34
1,increased LV ejection fraction,180 +/- 34,180 +/- 34
2,26 +/- 1,increasing MVO ( 2 ),
3,31 +/- 2,increasing MVO ( 2 ),
4,increasing MVO ( 2 ),180 +/- 34,180 +/- 34
5,257 +/- 41,increasing MVO ( 2 ),31 +/- 2
6,180 +/- 34,increasing MVO ( 2 ),

,Outcomes,Arm 1
0,intervention,CCM
1,increased LV peak +dP/dt,CCM
2,10.1 +/- 1.5 %,increased LV peak +dP/dt

,Outcomes,Arm 1
0,intervention,6.2 %
1,died,15.7 %
2,12.1 %,15.7 %
3,MI,15.7 %
4,15.7 %,died
5,death or MI,15.7 %

,Outcomes,Arm 1,Arm 2
0,intervention,SES,PES
1,rates of MACEs,two,two
2,5.9 % ( n = 5 ),PES,PES
3,SES,3.6 % ( n = 3 ),3.6 % ( n = 3 )
4,9.5 % ( n = 8 ),two,two
5,PES,3.6 % ( n = 3 ),3.6 % ( n = 3 )
6,definite stent thrombosis,two,two
7,1.2 % ( n = 1 ),PES,PES
8,3.6 % ( n = 3 ),two,two
9,two,PES,PES

,Outcomes,Arm 1
0,intervention,prophylaxis study
1,asymptomatic,normal
2,109,normal
3,duplex scans,normal
4,normal,duplex scans

,Outcomes,Arm 1
0,intervention,5.7 %
1,Two,excessive blood loss
2,5.7 %,excessive blood loss
3,excessive blood loss,coumadin

,Outcomes,Arm 1
0,intervention,219
1,One,clinically detectable proximal deep vein thrombosis
2,219,clinically detectable proximal deep vein thrombosis
3,clinically detectable proximal deep vein thrombosis,nonrandomized group

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,transfusions,standard care
1,130,randomly assigned,randomly assigned
2,8.3+/-3.3,randomly assigned,randomly assigned
3,63,67,67
4,randomly assigned,standard care,standard care
5,67,8.3+/-3.3,8.3+/-3.3

,Outcomes,Arm 1,Arm 2
0,intervention,transfusion group,standard-care
1,Ten,crossed over,crossed over
2,dropped out,transfusion,transfusion
3,two,crossed over,crossed over
4,crossed over,transfusion,transfusion

,Outcomes,Arm 2
0,intervention,standard-care
1,10,92 percent
2,cerebral infarctions,92 percent
3,1,92 percent
4,intracerebral hematoma,92 percent
5,infarction,92 percent
6,transfusion,92 percent
7,92 percent,transfusion

,Outcomes,Arm 1
0,intervention,wall motion and MCE assessment
1,sensitivity,82 % to 83 %
2,specificity,82 % to 83 %
3,82 % to 83 %,46 % to 55 %

,Outcomes,Arm 1,Arm 2
0,intervention,acarbose-treated,placebo
1,responders,placebo,placebo
2,20/24 patients,responders,10/19 patients
3,10/19 patients,responders,responders

,Outcomes,Arm 1,Arm 2
0,intervention,acarbose,placebo
1,mean daily insulin dose,placebo,placebo
2,16.4 +/- 10.1 IU,mean daily insulin dose,22.4 +/- 12.2 IU
3,22.4 +/- 12.2 IU,mean daily insulin dose,mean daily insulin dose

,Outcomes,Arm 1,Arm 2
0,intervention,120,137 +/- 44
1,higher metabolic effect,enalapril,enalapril
2,glibenclamide,enalapril,enalapril
3,AUC GIR,enalapril,enalapril
4,0-120,enalapril,enalapril
5,229 +/- 173,240,240
6,137 +/- 44,240,240
7,-1,enalapril,enalapril
8,120,240,240
9,240,enalapril,enalapril

,Outcomes,Arm 1
0,intervention,5.2 +/- 1.9
1,maximal metabolic effect,GIR ( max )
2,glibenclamide,-1
3,GIR ( max ),-1
4,5.2 +/- 1.9,4.1 +/- 1.3
5,4.1 +/- 1.3,-1
6,-1,-1

,Outcomes,Arm 1,Arm 2
0,intervention,1286 +/- 249,enalapril
1,total metabolic effect,0-600,0-600
2,glibenclamide,-1,-1
3,placebo,1267 +/- 334,
4,AUC GIR,-1,-1
5,0-600,-1,-1
6,1267 +/- 334,0-600,1286 +/- 249
7,1286 +/- 249,0-600,0-600
8,-1,1267 +/- 334,1286 +/- 249

,Outcomes,Arm 1
0,intervention,7.7 %
1,adverse events,2.9 %
2,dizziness,2.9 %
3,tinnitus,2.9 %
4,2.9 %,treatment-related events

,Outcomes,Arm 1,Arm 2
0,intervention,intervention and,intervention and
1,no,BP,control ;
2,change,BP,control ;
3,BP,BP,control ;
4,control ;,BP,no
5,-4.2 mmHg ( 95 % CI -12.4 to 3.9 ) /-2.6 mmHg ( 95 % CI -8.4 to 3.3 ),BP,control ;

,Outcomes,Arm 1
0,intervention,14
1,14,in-hospital deaths without relationship
2,in-hospital deaths without relationship,GLN

,Outcomes,Arm 1,Arm 2
0,intervention,3 of 8 patients,GLY placebo
1,Acute graft us host disease,.05,.05
2,1 of 10 hematologic patients,.05,.05
3,3 of 8 patients,.05,.05
4,.05,GLN,GLN

,Outcomes,Arm 1,Arm 2
0,intervention,40.5 %,50-mg
1,Response rates,27.3 %,27.3 %
2,50-mg,42.9 %,
3,40.5 %,panel,panel
4,36.4 %,42.9 %,panel
5,panel,27.3 %,27.3 %
6,42.9 %,27.3 %,27.3 %
7,27.3 %,42.9 %,panel

,Outcomes,Arm 1,Arm 2
0,intervention,20 mg,47.7 %
1,CBR,47.7 %,47.7 %
2,64.3 %,panel,61.4 %
3,61.4 %,panel,
4,panel,47.7 %,47.7 %
5,59.5 %,panel,61.4 %
6,47.7 %,panel,

,Outcomes,Arm 1,Arm 2
0,intervention,arzoxifene,50 mg
1,Mean observed steady-state plasma concentrations,50 mg,50 mg
2,3.62,7.48,7.48
3,7.48,3.62,3.62

,Outcomes,Arm 1,Arm 2
0,intervention,tourniquet,control
1,blood lost,0.0003,0.0003
2,1870 mL,0.0003,0.0003
3,95 %,0.0003,0.0003
4,1159-2580 mL,0.0003,0.0003
5,transfusion rates,0.0003,0.0003
6,7 %,0.0003,0.0003
7,79 %,0.0003,0.0003
8,0.0003,transfusion rates,transfusion rates

,Outcomes,Arm 1,Arm 2
0,intervention,fulvestrant,322 ( 76.1 % )
1,319 ( 74.5 % ),died,died
2,322 ( 76.1 % ),died,died
3,died,anastrozole,anastrozole

,Outcomes,Arm 1,Arm 2
0,intervention,fulvestrant,anastrozole
1,median overall survival,0.98 ; 95 %,0.98 ; 95 %
2,27.4 months,0.84-1.15,0.84-1.15
3,27.7 months,0.84-1.15,0.84-1.15
4,0.98 ; 95 %,0.84-1.15,0.84-1.15
5,0.84-1.15,0.98 ; 95 %,0.98 ; 95 %

,Outcomes,Arm 1,Arm 2
0,intervention,q.d .,b.i.d .
1,15-year actuarial locoregional recurrence rate,b.i.d .,b.i.d .
2,7 %,12 %,15-year actuarial locoregional recurrence rate
3,12 %,15-year actuarial locoregional recurrence rate,15-year actuarial locoregional recurrence rate

,Outcomes,Arm 1,Arm 2
0,intervention,q.d .,b.i.d .
1,rates of severe acute toxicity,b.i.d .,b.i.d .
2,4 %,42 %,42 %
3,q.d .,,5 %
4,5 %,42 %,42 %
5,b.i.d .,4 %,
6,moist desquamation,b.i.d .,b.i.d .
7,42 %,b.i.d .,b.i.d .

,Outcomes,Arm 1,Arm 2
0,intervention,q.d .,b.i.d.
1,15-year actuarial rate of severe late RT complications,b.i.d.,b.i.d.
2,two,q.d .,q.d .
3,6 %,15-year actuarial rate of severe late RT complications,15-year actuarial rate of severe late RT complications
4,11 %,two,two

,Outcomes,Arm 2,Arm 1
0,intervention,130,864
1,864,deaths,
2,breast cancers,control,133
3,133,breast cancers,
4,breast cancer deaths,control,133
5,896,breast cancers,133
6,130,breast cancers,133
7,deaths,control,133

,Outcomes,Arm 1,Arm 2
0,intervention,tamoxifen,7 %
1,higher mean hot flash score,exemestane,exemestane
2,daily hot flashes,exemestane,exemestane
3,33 %,increase from,increase from
4,7 %,increase from,increase from
5,increase from,exemestane,exemestane

,Outcomes,Arm 1
0,intervention,group A
1,objective response rate,group A
2,18 %,objective response rate
3,27.5 %,objective response rate

,Outcomes,Arm 1,Arm 2
0,intervention,3 %,group B
1,rate and grade 3 and 4 neutropenia,group B,
2,23,,3 %

,Outcomes,Arm 1,Arm 2
0,intervention,3840 +/- 298,13.6 +/- 2.49
1,reduction of mean duration of air leak,3840 +/- 298,5160 +/- 3890
2,4.9 +/- 1.79,hospital stay cost per patient,hospital stay cost per patient
3,8.2 +/- 4.2,leva,
4,number of days of a chest tube duration,3840 +/- 298,5160 +/- 3890
5,7.3 +/- 1.14,hospital stay cost per patient,5160 +/- 3890
6,12.46 +/- 3.6,leva,
7,length of postoperative in-hospital stay in days,3840 +/- 298,5160 +/- 3890
8,9.4 +/- 1.86,hospital stay cost per patient,hospital stay cost per patient
9,13.6 +/- 2.49,leva,
10,hospital stay cost per patient,3840 +/- 298,5160 +/- 3890
11,leva,hospital stay cost per patient,5160 +/- 3890
12,3840 +/- 298,hospital stay cost per patient,hospital stay cost per patient
13,5160 +/- 3890,leva,hospital stay cost per patient

,Outcomes,Arm 1
0,intervention,17.9 % ( 41/229 )
1,HER2 overexpression/amplification,37.3 % ( 91/244 )

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,PSA-D,PSA-T
1,higher area under the ROC curve,PSA-T,PSA-T
2,0.77,0.79,higher area under the ROC curve
3,0.79,higher area under the ROC curve,0.77

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,response rates,arm B,arm B
2,22.0,28.9,response rates
3,28.9,response rates,response rates

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median time to treatment failure,arm B,arm B
2,3.6 months,Median time to treatment failure,Median time to treatment failure
3,4.8 months,Median time to treatment failure,Median time to treatment failure

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median time to progression,arm B,arm B
2,4.1 months,Median time to progression,Median time to progression
3,5.5 months,Median time to progression,Median time to progression

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median survival time,arm B,arm B
2,15.5 months,Median survival time,18.8 months
3,18.8 months,Median survival time,Median survival time

,Outcomes,Arm 1,Arm 2
0,intervention,bimatoprost,latanoprost
1,Ocular irritation,latanoprost,latanoprost
2,22 subjects (37.9%),13 subjects (22.4%),ocular hyperaemia
3,ocular hyperaemia,latanoprost,latanoprost
4,13 subjects (22.4%),ocular hyperaemia,ocular hyperaemia

,Outcomes,Arm 1,Arm 2
0,intervention,TRA/TIM BAK-free group,TRA/TIM group
1,hyperemia of the eye,TRA/TIM group,TRA/TIM group
2,ocular hyperemia and conjunctival hyperemia,TRA/TIM group,TRA/TIM group
3,11.8%,13.0%,ocular hyperemia and conjunctival hyperemia
4,13.0%,ocular hyperemia and conjunctival hyperemia,ocular hyperemia and conjunctival hyperemia

,Outcomes,Arm 1,Arm 2
0,intervention,350- and,500-mm2
1,postoperative visual acuities remained within one line of the preoperative visual acuities,350- and,500-mm2
2,62%,postoperative visual acuities remained within one line of the preoperative visual acuities,66%
3,66%,62%,postoperative visual acuities remained within one line of the preoperative visual acuities
4,500-mm2,62%,

,Outcomes,Arm 1,Arm 2
0,intervention,0.15,BPL
1,global subjective ocular symptom score,BPL,BPL
2,BPL,0.15,
3,0.15,0.46,0.46
4,0.41,0.18,0.18
5,0.18,0.46,0.46
6,0.46,0.18,0.18

,Outcomes,Arm 1,Arm 2
0,intervention,Brimonidine,timolol
1,overall mean peak reduction in intraocular pressure (IOP),mean peak reduction in IOP,mean peak reduction in IOP
2,6.5 mm Hg,6.1 mm Hg,mean peak reduction in IOP
3,mean peak reduction in IOP,6.1 mm Hg,timolol
4,6.1 mm Hg,mean peak reduction in IOP,mean peak reduction in IOP

,Outcomes,Arm 1,Arm 2
0,intervention,alginate carteolol,standard
1,mean reductions from baseline in intraocular pressure,standard,standard
2,6.32+/-2.87,mean reductions from baseline in intraocular pressure,5.67+/-3.30
3,5.67+/-3.30,mean reductions from baseline in intraocular pressure,mean reductions from baseline in intraocular pressure

,Outcomes,Arm 1,Arm 2
0,intervention,11.17,TTFC
1,Mean IOP reductions,TTFC,TTFC
2,11.34,7.89,7.89
3,6.42,11.17,11.17
4,11.17,Mean IOP reductions,Mean IOP reductions
5,7.89,11.17,11.17
6,TTFC,11.34,

,Outcomes,Arm 1,Arm 2
0,intervention,6.2 mmHg (27.0%),brimonidine-timolol
1,mean additional reduction from latanoprost-treated baseline IOP,10,10
2,8.3 mmHg (35.5%),mean additional reduction from latanoprost-treated baseline IOP,6.2 mmHg (27.0%)
3,6.2 mmHg (27.0%),mean additional reduction from latanoprost-treated baseline IOP,mean additional reduction from latanoprost-treated baseline IOP
4,10,brimonidine-timolol,6.2 mmHg (27.0%)

,Outcomes,Arm 1,Arm 2
0,intervention,group BSS,Ringer
1,no,Ringer,Ringer
2,CV increase,Ringer,Ringer
3,23.0 ± 3.0%,CV increase,CV increase
4,Ringer,23.0 ± 3.0%,
5,20.2 ± 4.0%,23.0 ± 3.0%,CV increase

,Outcomes,Arm 1,Arm 2
0,intervention,2.54,bimatoprost
1,mean IOP levels,latanoprost/timolol,bimatoprost
2,latanoprost/timolol,,3.28
3,13.83,latanoprost/timolol,3.28
4,2.54,,3.28
5,16.16,latanoprost/timolol,3.28
6,3.28,latanoprost/timolol,16.16

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,latanoprost
1,127,61,55
2,55,latanoprost,latanoprost
3,66,61,55
4,61,55,55

,Outcomes,Arm 1,Arm 2
0,intervention,tafluprost,timolol
1,conjunctival hyperemia,timolol,timolol
2,4.4%,conjunctival hyperemia,1.2%
3,1.2%,conjunctival hyperemia,conjunctival hyperemia

,Outcomes,Arm 1,Arm 2
0,intervention,latanoprost plus timolol group,dorzolamide plus timolol group
1,least square estimate of the mean diurnal intraocular pressure reduction,dorzolamide plus timolol group,dorzolamide plus timolol group
2,-7.06 mm Hg,least square estimate of the mean diurnal intraocular pressure reduction,-4.44 mm Hg
3,-4.44 mm Hg,-7.06 mm Hg,least square estimate of the mean diurnal intraocular pressure reduction
4,dorzolamide plus timolol group,-7.06 mm Hg,

,Outcomes,Arm 1,Arm 2
0,intervention,study group,control group
1,mean baseline intraocular pressure,control group,control group
2,23.8 +/- 12.6 mmHg,mean baseline intraocular pressure,mean baseline intraocular pressure
3,25.9 +/- 10.6 mmHg,mean baseline intraocular pressure,mean baseline intraocular pressure

,Outcomes,Arm 1,Arm 2
0,intervention,Ahmed,Baerveldt
1,Mean durations of follow-up,Baerveldt,Baerveldt
2,20.0 months,Mean durations of follow-up,22.9 months
3,22.9 months,Mean durations of follow-up,Mean durations of follow-up

,Outcomes,Arm 1,Arm 2
0,intervention,Ahmed,Baerveldt
1,Cumulative successes,Baerveldt,Baerveldt
2,0.73,0.85,0.85
3,0.62,0.92,0.92
4,cumulative successes,0.85,0.85
5,Baerveldt,0.73,
6,0.92,cumulative successes,cumulative successes
7,0.85,0.92,0.92

,Outcomes,Arm 1,Arm 2
0,intervention,laser group,control group
1,proportion of eyes started on medical treatment,control group,control group
2,2,9 eyes (17%),proportion of eyes started on medical treatment
3,8 eyes (15%,control group,control group
4,9 eyes (17%),2,2

,Outcomes,Arm 1,Arm 2
0,intervention,study group,control group
1,Forty-three,12,12
2,25,12,12
3,completed the study,12,12
4,12,completed the study,completed the study

,Outcomes,Arm 1,Arm 2
0,intervention,dorzolamide/timolol,dorzolamide/timolol
1,mean (standard error of mean [SE]) IOP reductions at months one,dorzolamide/timolol,dorzolamide/timolol
2,7.2 (0.4),7.4 (0.3) mm Hg,7.4 (0.3) mm Hg
3,7.3 (0.4),7.4 (0.3) mm Hg,7.4 (0.3) mm Hg
4,7.1 (0.3) mm Hg,7.4 (0.3) mm Hg,7.4 (0.3) mm Hg
5,7.5 (0.3),7.4 (0.3) mm Hg,7.4 (0.3) mm Hg
6,7.8 (0.3),7.4 (0.3) mm Hg,7.4 (0.3) mm Hg
7,7.4 (0.3) mm Hg,7.5 (0.3),7.8 (0.3)

,Outcomes,Arm 1,Arm 2
0,intervention,fixed-combination,latanoprost
1,at least 1 treatment-emergent AE,latanoprost,latanoprost
2,10.9%,12.1%,at least 1 treatment-emergent AE
3,12.1%,at least 1 treatment-emergent AE,at least 1 treatment-emergent AE

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,timolol
1,Clinical success,timolol,timolol
2,71% (75/106),Clinical success,Clinical success
3,70% (73/105),Clinical success,Clinical success

,Outcomes,Arm 1,Arm 2
0,intervention,lidocaine,BSS
1,125 of 277 patients (45.1%),123 of 229 patients (53.7%),123 of 229 patients (53.7%)
2,pain,BSS,BSS
3,123 of 229 patients (53.7%),pain,pain

,Outcomes,Arm 1,Arm 2
0,intervention,dorzolamide,dorzolamide
1,corresponding figures,dorzolamide,dorzolamide
2,27.2 (3.4),,corresponding figures
3,5.6 (2.6),27.2 (3.4),corresponding figures

,Outcomes,Arm 1,Arm 2
0,intervention,SLT,ALT
1,No,two,two
2,mean decrease in IOP,two,two
3,5.86 mm Hg,mean decrease in IOP,mean decrease in IOP
4,6.04 mm Hg,mean decrease in IOP,mean decrease in IOP
5,two,mean decrease in IOP,mean decrease in IOP

,Outcomes,Arm 1,Arm 2
0,intervention,350-mm2,500-mm2
1,Visual acuities,500-mm2,500-mm2
2,50%,Visual acuities,Visual acuities
3,46%,Visual acuities,Visual acuities

,Outcomes,Arm 1,Arm 2
0,intervention,viscocanalostomy,trabeculectomy
1,Mean baseline IOP,trabeculectomy,trabeculectomy
2,24.0+/-2.0 mmHg,Mean baseline IOP,23.7+/-2.6 mmHg
3,viscocanalostomy,,23.7+/-2.6 mmHg
4,23.7+/-2.6 mmHg,viscocanalostomy,viscocanalostomy
5,trabeculectomy,24.0+/-2.0 mmHg,

,Outcomes,Arm 1,Arm 2
0,intervention,microtrabeculectomy,microtrabeculectomy
1,mean intraocular pressure,0.89,0.89
2,cumulative probability of failure,0.89,0.89
3,12.4 ± 4.6 mmHg,cumulative probability of failure,0.27
4,0.28,0.89,0.89
5,11.5 ± 3.6 mmHg,cumulative probability of failure,0.27
6,0.27,0.89,0.89
7,0.89,11.5 ± 3.6 mmHg,0.27

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,latanoprost
1,clinical success at month 3,latanoprost,latanoprost
2,91%,clinical success at month 3,74%
3,74%,clinical success at month 3,clinical success at month 3

,Outcomes,Arm 1,Arm 2
0,intervention,trabeculectomy,Ex-PRESS implantation
1,mean pre-operative IOP,Ex-PRESS implantation,Ex-PRESS implantation
2,31.1 (± 14.2) to 16.2 (± 1.5) mm Hg,mean pre-operative IOP,mean pre-operative IOP
3,28.1 (± 9.0) to 15.7 (± 1.8) mm Hg,31.1 (± 14.2) to 16.2 (± 1.5) mm Hg,mean pre-operative IOP
4,Ex-PRESS implantation,31.1 (± 14.2) to 16.2 (± 1.5) mm Hg,

,Outcomes,Arm 1,Arm 2
0,intervention,0.005%,0.0015%
1,reduced IOP (+/- SEM),0.0015%,0.0015%
2,latanoprost,,9.8 +/- 0.9 mm Hg
3,9.8 +/- 0.9 mm Hg,6.7 +/- 0.9 mm Hg,reduced IOP (+/- SEM)
4,6.7 +/- 0.9 mm Hg,reduced IOP (+/- SEM),9.8 +/- 0.9 mm Hg

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,ologen
1,absolute success rate,ologen,ologen
2,100%,absolute success rate,50%
3,MMC,,50%
4,50%,absolute success rate,absolute success rate

,Outcomes,Arm 1,Arm 2
0,intervention,25.2,bimatoprost
1,reduced IOP (mean (SD)),bimatoprost,bimatoprost
2,8.4 (3.8) mm Hg,3.6,3.6
3,bimatoprost,25.2,
4,8.9 (3.9) mm Hg,3.6,3.6
5,25.2,3.6,3.6
6,3.6,3.6,3.6

,Outcomes,Arm 1,Arm 2
0,intervention,intracameral lidocaine,BSS
1,median pain score (range),BSS,BSS
2,0.0,median pain score (range),median pain score (range)
3,1.0,median pain score (range),median pain score (range)

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,control
1,30%,control,control
2,probability of success,control,control
3,62%,probability of success,67%
4,67%,probability of success,probability of success

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,81.8%
1,clinical success rate,no,no
2,86.2%,no,no
3,81.8%,no,no
4,no,timolol,timolol

,Outcomes,Arm 1,Arm 2
0,intervention,350- and,11%
1,serous choroidal effusion,11%,11%
2,16%,corneal or corneal graft edema,corneal or corneal graft edema
3,32%,11%,11%
4,strabismus,11%,11%
5,19%,11%,11%
6,anterior uveitis,11%,11%
7,14%,corneal or corneal graft edema,corneal or corneal graft edema
8,11%,corneal or corneal graft edema,corneal or corneal graft edema
9,corneal or corneal graft edema,11%,11%

,Outcomes,Arm 1,Arm 2
0,intervention,dorzolamide/timolol,2
1,mean daytime diurnal IOP,2,2
2,18.9 mmHg,2,2
3,18.4 mmHg,dorzolamide/timolol,17.5
4,latanoprost,17.4 mmHg,1
5,17.4 mmHg,2,2
6,dorzolamide/timolol,mean daytime diurnal IOP,17.5
7,17.5,2,2
8,2,17.4 mmHg,

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,5-FU
1,intraocular pressures,5-FU,5-FU
2,10.9 +/- 5.3 mmHg,60.0%,21.1%
3,MMC,,21.1%
4,14.2 +/- 5.5 mmHg,MMC,MMC
5,5-FU,60.0%,21.1%
6,less than or equal to 12 mmHg,5-FU,5-FU
7,60.0%,less than or equal to 12 mmHg,21.1%
8,21.1%,MMC,MMC

,Outcomes,Arm 1,Arm 2
0,intervention,laser group,6%
1,Eight,converted to glaucoma,converted to glaucoma
2,15%,converted to glaucoma,converted to glaucoma
3,3,converted to glaucoma,converted to glaucoma
4,6%,converted to glaucoma,converted to glaucoma
5,control group,15%,
6,converted to glaucoma,control group,control group

,Outcomes,Arm 1
0,intervention,alginate
1,blurred vision sensation,alginate
2,2 out of 74 patients,blurred vision sensation

,Outcomes,Arm 1,Arm 2
0,intervention,14 eyes,7 eyes
1,14 eyes,first,first
2,shallower anterior,first,first
3,7 eyes,first,first
4,first,group B,group B

,Outcomes,Arm 1,Arm 2
0,intervention,PCG,non-PCG
1,Responder rates,non-PCG,non-PCG
2,latanoprost,46%,57%
3,timolol,72%,
4,50%,46%,57%
5,46%,72%,Responder rates
6,72%,non-PCG,non-PCG
7,57%,72%,Responder rates
8,non-PCG,72%,

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,OLO
1,mean preoperative IOP,OLO,OLO
2,26.5 (±5.2),mean preoperative IOP,mean preoperative IOP
3,27.3 (±6.0),mean preoperative IOP,mean preoperative IOP

